EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

First-in-Class Immuno-Oncology Drug APG157DS Repolarizes Innate Immune Cells and Induces Durable Remission in a Syngeneic Glioblastoma Model

Shubhasmita Mohapatra, Adrian Guerrero iD, Neha Rahman iD, Stefan Markovic, Lauren O'Donnell iD, Youssef Zaim Wadghiri, Khondoker Takia Zaman, Luis Avila, Parag Mehta, Probal Banerjee iD

International Journal of Molecular Sciences · 27.07.2026 · 27 (15) · 6687

DOI: 10.3390/ijms27156687 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 27.07.2026. Verfasst von Shubhasmita Mohapatra und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Chemistry, The College of Staten Island (CUNY), Staten Island, NY 10314, USA. Hauptthemen laut MEDLINE: Glioblastoma, Immunity, Innate, Brain Neoplasms. Die Arbeit nennt 56 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, NIBIB NIH HHS, NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

APG157DS is a multi-component investigational drug which is currently the subject of multiple cancer trials. It has shown promising efficacy in patients with head and neck cancer. We report its immuno-modulatory effect in a syngeneic mouse model of glioblastoma (GBM). Long-term treatment with APG157DS led to durable tumor remission in 50% of mice, while all vehicle-treated mice reached humane endpoints within 42 days. Mechanistically, the drug induced selective repolarization of tumor-associated macrophages (TAMs) from an immunosuppressive Arg1high/iNOSlow phenotype to a tumoricidal Arg1low/iNOShigh state, accompanied by increased intratumoral recruitment of activated (NKp46+) natural killer cells and CD8+ cytotoxic T-cells. APG157DS also suppressed vascular endothelial growth factor (VEGF) and Hypoxia-inducible factor 1-alpha (HIF-1α) expression in tumors, further impairing tumor growth. Notably, APG157DS did not elicit off-target macrophage activation in peripheral tissues such as the spleen, highlighting its selective immune targeting. These findings provide a mechanistic rationale for further clinical development of APG157DS in GBM and potentially other immune-evasive cancers.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

GlioblastomaImmunity, InnateBrain NeoplasmsAnimalsMiceTumor-Associated MacrophagesDisease Models, AnimalCell Line, TumorKiller Cells, NaturalHumansVascular Endothelial Growth Factor AMacrophages

Stichwörter der Autor:innen

APG157DSArg1/iNOSM2/M1curcuminglioblastomatumor-associated microglia and macrophages (TAMs)

Substanzen

Vascular Endothelial Growth Factor A

Autor:innen und Institutionen

  • Department of Chemistry, The College of Staten Island (CUNY), Staten Island, NY 10314, USA.
  • Doctoral Program in Biochemistry, The College of Staten Island (CUNY), New York, NY 10314, USA.
  • Department of Radiology, Bernard and Irene Schwartz Center for Biomedical Imaging & Center for Advanced Imaging Innovation and Research and Preclinical Imaging, Division for Advanced Research Technologies, New York Univ…
  • Aveta Biomics, Inc., 110 Great Road, Suite 302, Bedford, MA 01730, USA.
  • Center for Developmental Neuroscience, The College of Staten Island (CUNY), Staten Island, NY 10314, USA.

ORCID-Profile: Adrian Guerrero, Neha Rahman, Lauren O'Donnell, Probal Banerjee

Förderung

  • NCI NIH HHS
  • NIBIB NIH HHS
  • NIH HHS
  • Aveta Biomics, Inc.
  • NYU Grossman School of Medicine Preclinical Imaging Laboratory
  • the Laura and Isaac Perlmutter Cancer Center Support Grant
  • the NIBIB Biomedical Technology Resource Center Grant

Zitieren

APA

Mohapatra, S., Guerrero, A., Rahman, N., Markovic, S., O'Donnell, L., Wadghiri, Y. Z., Zaman, K. T., Avila, L., Mehta, P., & Banerjee, P. (2026). First-in-Class Immuno-Oncology Drug APG157DS Repolarizes Innate Immune Cells and Induces Durable Remission in a Syngeneic Glioblastoma Model. International Journal of Molecular Sciences, 27(15), 6687. https://doi.org/10.3390/ijms27156687

Vancouver

Mohapatra S, Guerrero A, Rahman N, Markovic S, O'Donnell L, Wadghiri YZ, et al. First-in-Class Immuno-Oncology Drug APG157DS Repolarizes Innate Immune Cells and Induces Durable Remission in a Syngeneic Glioblastoma Model. International Journal of Molecular Sciences. 2026;27(15):6687. doi:10.3390/ijms27156687

BibTeX
@article{Mohapatra2026,
  author = {Mohapatra, Shubhasmita and Guerrero, Adrian and Rahman, Neha and Markovic, Stefan and O'Donnell, Lauren and Wadghiri, Youssef Zaim and Zaman, Khondoker Takia and Avila, Luis and Mehta, Parag and Banerjee, Probal},
  title = {First-in-Class Immuno-Oncology Drug APG157DS Repolarizes Innate Immune Cells and Induces Durable Remission in a Syngeneic Glioblastoma Model},
  journal = {International Journal of Molecular Sciences},
  year = {2026},
  volume = {27},
  number = {15},
  pages = {6687},
  doi = {10.3390/ijms27156687}
}
Kostenlos starten →